Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, th...
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Taylor & Francis
2018-01-01
|
| Reeks: | Hepatic Oncology |
| Onderwerpen: | |
| Online toegang: | https://www.futuremedicine.com/doi/10.2217/hep-2017-0020 |